Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay

Bone Marrow Transplantation
Hiroyasu OgawaH Sugiyama

Abstract

We report here that a patient with relapsed AML after allogeneic bone marrow transplantation achieved and maintained complete remission (CR) after effective donor leukocyte transfusion (DLT), without the occurrence of GVHD and marrow aplasia, for more than 21 months. This continuous CR maintenance is mainly due to the application of DLT at molecular relapse that was diagnosed by monitoring minimal residual disease (MRD) by the quantitation of WT1 (Wilms tumor gene) expression levels (WT1 assay). The present case demonstrates that early application of DLT at molecular relapse is essential for the improvement of the efficacy of DLT for relapsed AML after BMT.

Citations

May 25, 2001·International Journal of Hematology·H Sugiyama
Aug 31, 2002·Journal of Hematotherapy & Stem Cell Research·Elizabeth Algar
Sep 25, 2009·The Tohoku Journal of Experimental Medicine·Yuichi SakamotoTadao Funato
Jun 30, 2004·Leukemia & Lymphoma·Hiroyasu OgawaHiroya Tamaki
Jun 20, 2008·Biology Direct·Dustin T HollowayCharles DeLisi
May 27, 2008·Current Opinion in Immunology·Yoshihiro OkaHaruo Sugiyama
May 12, 2009·Leukemia Research·Adriana LasaJosep F Nomdedéu
Jan 3, 2019·Cancer Investigation·Elizabeth A Fry, Kazushi Inoue
Dec 7, 2002·Blood·Julia A AlbertaDavid Housman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.